Data from the Centers for Disease Control (CDC) National Health and Nutrition Examination
Survey (NHANES) (ClinicalTrials.gov Identifier: NCT00005154) are combined in this
computational experiment with data on shipments from food ingredient manufacturers to
evaluate exposure of the US population through foods to a possible pharmaceutical formulation
ingredient, beta cyclodextrin (Campbell et al. 2020).
Every year more food codes are added to categories of foods permitted to incorporate
BCD. By 2020 nearly 600 food codes containing BCD may be listed in the FNDDS. (Lodder 2017)
BCD use is increasing in terms of the number of foods approved for BCD incorporation, and in
2016 69.17% of the total U.S. population of 2+ years were established as consumers of BCD
based on the approved food uses. However, the mean intakes of BCD by the 2016 BCD
consumers from all approved food uses were estimated to be 12.4 mg/person/day or 0.2 mg/kg
body weight/day, a slight decrease from 2014 (Lodder, 2017). The heavy consumer (90th
percentile all-user) intakes of BCD from all approved food-uses were estimated to be 30.3
mg/person/day or 0.5 mg/kg body weight/day.
Campbell, H.R., Cecil, R.P., Lodder. R., 2020. Population Data-Driven Formulation of a COVID-19 Therapeutic. Contact in Context, doi: https://doi.org/10.1101/2020.07.24.20161547
Lodder, R.A., 2017. Data-Driven Design of an Ebola Therapeutic. Procedia Comput. Sci.
108, 1612–1621. https://doi.org/10.1016/j.procs.2017.05.127
The featured image is from m.cyclodextrinchina.com